Completes $300M Cullgen Acquisition, Appoints New CEO/President and CFO, Expanding Pipeline and Leadership

summarizeSummary

Gyre Therapeutics completed its $300 million all-stock acquisition of Cullgen Inc., appointing new executive leadership and expanding its pipeline to become a fully integrated biopharmaceutical company.

check_boxKey Events

• Acquisition of Cullgen Inc. Completed

  Gyre Therapeutics, Inc. consummated the previously announced all-stock acquisition of Cullgen Inc., valued at approximately $300 million. Cullgen is now a wholly-owned subsidiary, establishing Gyre as a U.S.- and China-based fully integrated biopharmaceutical company with an expanded pipeline.

• New CEO and President Appointed

  Dr. Ying Luo, former CEO of Cullgen, has been appointed Chief Executive Officer and President of Gyre Therapeutics and joined the Board of Directors. Ping Zhang will continue as Chairman of the Board.

• New Chief Financial Officer Appointed

  Thomas Eastling has been appointed Chief Financial Officer, succeeding Ruoyu Chen, who resigned. Mr. Eastling also resigned from the Board of Directors.

• Board of Directors Changes

  Thomas Eastling and Songjiang Ma resigned from the Board, reducing its size to seven directors. Mr. Ma also resigned from his position as President of the Company.

auto_awesomeAnalysis

This 8-K filing confirms the completion of Gyre Therapeutics' previously announced all-stock acquisition of Cullgen Inc., valued at approximately $300 million. While the transaction is structured as a combination of entities under common control (both previously controlled by GNI Group Ltd.), it represents a significant strategic shift for Gyre. The acquisition brings a revenue-producing commercial asset and a robust pipeline of targeted protein degraders and degrader-antibody conjugates, transforming Gyre into a U.S.- and China-based fully integrated biopharmaceutical company. The comprehensive leadership changes, including the appointment of Dr. Ying Luo as the new CEO and President and Thomas Eastling as CFO, underscore the integration and new strategic direction. The issuance of Series B Convertible Preferred Stock as part of the all-stock consideration, convertible into common stock upon shareholder approval (as detailed in the April 27, 2026 DEF 14A filing), is a material financing component of this transformative deal. Investors should monitor the integration progress and the shareholder vote on the preferred stock conversion.